瑞舒伐他汀钙对低密度脂蛋白与高密度脂蛋白比值和脂蛋白a干预效果的研究

目的:评价药物瑞舒伐他汀钙对低密度脂蛋白与高密度脂蛋白比值(LDL-C/HDL-C)和脂蛋白a[Lp(a)]的干预效果和安全性。方法:以辛伐他汀为对照,采用随机平行组间对照研究的方法,将筛选合格的受试者随机分配为A组40例、B组40例(A=瑞舒伐他汀10mg,B=辛伐他汀20mg)连续8周。分别于受试后的第4周和第8周随访。观察调脂疗效和不良反应,进行数据统计。结果:瑞舒伐他汀与辛伐他汀组在治疗第4周、第8周LDL-C/HDL-C均有显著下降(P0.05),瑞舒伐他汀治疗效果均优于辛伐他汀。瑞舒伐他汀与辛伐他汀治疗4周时Lp(a)水平均有下降,但2组差异无统计学意义。治疗8周时,瑞舒伐他汀组Lp(a)明显下降,且效果优于辛伐他汀组,差异有统计学意义(P0.05)。结论:瑞舒伐他汀可显著降低LDL-C/HDL-C和Lp(a)的水平,且有良好安全性。

Cnnical study of the effectiveness of Rosuvastatin on LDL-C/HDL-C and Lp(a)

Objective：To observe the effectiveness and safety of Rosuvastatin on LDL-C/HDL-C and Lp（a）.Methods：Rosuvastatin was used as the experimental drug and simvastatin as the control.Eighty patients were enrolled and randomly divided into two groups（group A and group B）.Patients took Rosuvastatin 10 mg in group A（n = 40） and took simvastatin 20 mg in group B（n = 40） before go to bed or three hours after supper every evening for 8 weeks.Each patient must keep the same diet and living habit in order to insure the comparability between the two groups and the patients were followed up at the 4th week and 8th week,blood lipid test,liver and kidney founction test,blood routine and urine routine were evaluated.Results：Both of Rosuvastatin and simvastatin decreased the level of LDL-C/HDL-C at the 4th week from [（4.39 ± 0.13） to（3.14 ±0.12） in group A and（4.37 ±0.21） to（3.34 ±0.19） in group B]and at the 8th week the level of LDL-C/HDL-C were（2.06 ± 0.31） in group A and（2.45 ± 0.16） in group B）,however,the effectiveness of Rosuvastatin was better than simvastatin at both the 4th week and the 8th week（P 0.05）.Both of the two drugs decreased Lp（a） in the 4th week,but there are no significant differences between the two groups（P 0.05）.In the 8th week,Rosuvastatin lowered Lp（a） more than simvastatin 〔from（42.00 ± 3.22） mmol/L to（30.92 ±1.98） mmol/L in group A and from（44.45 ±2.34） mmol/L to（34.01 ±1.54） mmol/L in group B,P 0.05〕.Serious adverse effects of Rosuvastatin and simvastatin such as damage to liver or rhabdomyolysis as reported before were not found in the two groups.Conclusion：Rosuvastatin can significantly decrease LDLC/HDL-C and Lp（a） and is superior than simvastatin.Rosuvastatin is safe for clinical use and patients tolerate it well.